1-Deoxy-D-xylulose 5-phosphate reductoisomerase (Dxr) is a key enzyme in a biosynthetic pathway for isoprenoids that is unique to eubacteria and plants. Dxr catalyzes the rearrangement and NADPH-dependent reduction of 1-deoxy-D-xylulose 5phosphate to 2-C-methyl-D-erythritol 4-phosphate. The authors have purified Escherichia coli Dxr and devised a highthroughput screen (HTS) for compounds that bind to this enzyme at a functional site. Evidence is presented that the surrogate ligand directly binds or allosterically affects both the D-1-deoxyxylulose 5-phosphate (DXP) and NADPH binding sites. Compounds that bind at either or both sites that compete for binding with the surrogate ligand register as hits. The timeresolved fluorescence-based assay represents an improvement over the Dxr enzyme assay that relies on relatively insensitive measurements of NADPH oxidation. Screening 32,000 compounds from a diverse historical library, the authors obtained 89 potent inhibitors in the surrogate ligand competition assay. The results presented here suggest that peptide surrogate ligands may be useful in formatting HTS for proteins with difficult biochemical assays or targets of unknown function. (Journal of Biomolecular Screening 2003:332-339) 
INTRODUCTION
I N CONTRAST TO ANIMALS, which use the mevalonate pathway for isopentenyl diphosphate (IPP) synthesis, eubacteria and plants use the deoxyxylulose pathway that is mevalonate independent. 1 The existence of this pathway represents an opportunity for discovery of novel and selective antibiotics and herbicides. IPP is the building block for the biosynthesis of isoprenoids, a large and diverse category of molecules that function as electron transport components in bacteria, photosynthetic pigments in plants, and steroid hormones in mammals. In the mevalonate-independent pathway for the biosynthesis of IPP, pyruvate is decarboxylated, and the resulting hydroxyethylthiamine reacts with glyceraldehyde-3-phosphate to form D-1-deoxyxylulose 5-phosphate (DXP). 2, 3 DXP undergoes a rearrangement of its carbon skeleton followed by NADPH-dependent reduction to form 2-C-methyl-Derythritol 4-phosphate (MEP). [4] [5] [6] MEP is converted to IPP and dimethylallyl diphosphate in a series of reactions catalyzed by IspD, IspE, IspF, IspG, and IspH. [7] [8] [9] [10] [11] [12] [13] [14] The enzyme that catalyzes the conversion of DXP to MEP is 1deoxy-D-xylulose 5-phosphate reductoisomerase, 4, 5 or Dxr (formerly known as YaeM and currently also known as IspC and DOXP reductoisomerase); the reaction is shown in Figure 1 . The gene encoding Dxr has been found in a variety of bacterial pathogens as well as the malaria parasite Plasmodium falciparum. 15, 16 Inhibitors that target Dxr are expected to be toxic to organisms that use this enzyme. In support of this prediction, the Dxr inhibitor fosmidomycin, 17 a natural product of Streptomyces, has strong antibacterial activity against many gram-negative and some grampositive bacteria 18, 19 and is an effective antimalarial agent. 16 Fosmidomycin presumably mimics the aldehyde intermediate that is produced by isomerization of DXP before reduction 17 (Fig. 1) .
We have taken a target-directed approach to the discovery of new Dxr inhibitors. This approach is based on competition of a "surrogate ligand" by library compounds. Ligand-binding assays have been used successfully in high-throughput screening (HTS) for many years; for recent examples, see Daugherty et al., 20 Parker et al., 21 Valenzano et al., 22 and Allen et al. 23 In this case, the surro-gate ligand is a peptide identified by phage display that binds specifically to the target protein. We have previously shown that peptides can be potent and specific inhibitors of enzyme function. 24 However, issues of pharmacokinetic stability, oral availability, and membrane impermeability are deterrents in developing such peptides as drugs. Therefore, we have formatted a time-resolved fluorescence (TRF)-based assay in which binding to a target by a peptide is competed by low molecular weight library compounds more suitable for drug development. Compounds with the right stereochemical and charge characteristics should mimic molecular contacts with the target that are made by the peptide. Applying this technology to Dxr in an HTS, we have discovered novel Dxr inhibitors that are potent and specific and that fall into structurally related groups.
MATERIALS AND METHODS

Reagents
Unless otherwise stated, reagents were from Sigma Chemical Company (St. Louis, MO). DXP was from Echelon Research Laboratories (Salt Lake City, UT). Fosmidomycin was from Molecular Probes (Eugene, OR). Screening compounds were from Specs (Rijswijk, the Netherlands). Europium-conjugated streptavidin (Wallac DELFIA reagent 1244-360) and enhancement solution (Wallac DELFIA reagent 1244-105) were from Perkin-Elmer (Boston, MA). PCR was carried out using the Expand High-Fidelity PCR System (Roche, Indianapolis, IN) in conjunction with the Techne Genius thermal cycler (Techne, Princeton, NJ). Purification of DNA was done using kits purchased from Qiagen (Valencia, CA). Restriction enzymes and DNA ligase were from New England Biolabs (NEB, Beverly, MA). DNA sequencing was performed by Sequetech (Mountain View, CA). Oligonucleotides were synthesized by the Midland Certified Reagent Company (Midland, TX). Peptides were synthesized by AnaSpec (San Jose, CA).
DXP reductoisomerase expression and purification
The gene encoding Dxr was amplified by PCR from Escherichia coli strain B genomic DNA. The forward PCR primer encodes the 5′ end of the yaeM (dxr) gene and contains an NdeI site (italicized): 5′ATGATCGACATATGAAGCAACTCACCATTCTGGGC. The reverse PCR primer is complementary to the 3′ end of the yaeM gene but lacks the stop codon (to allow production of a fusion protein) and contains a SmaI site (italicized): 5′GATCGACCCGGGGCTTGCGAGACGCATCACCTCTTTT CTGGC. The PCR product was 1997 bp in length and was cut with the restriction enzymes NdeI and SmaI. This DNA fragment was then ligated into the IMPACT system protein expression vector CYB2 (NEB) that had been cut with NdeI and SmaI, using T4 DNA ligase. The resulting construct encoding a Dxr-intein-chitin binding domain (CBD) fusion protein was transformed into E. coli strain JS5 (Biorad, Hercules, CA). The plasmid DNA was isolated and sequenced, confirming that the sequence at the amino acid level was the same as published. 5 Coomassie-stained gels of isopropyl-1-thio-β-D-galactopyranoside-induced cells confirmed expression of the fusion protein. The gene was later cut out of the CYB2 vector with the same restriction enzymes used for the initial cloning and ligated into the vector TYB2AT, a vector based on TYB2 (NEB) but altered to include a 15-amino acid in vivo biotinylation signal at the C-terminus of Dxr. The resulting construct was then transformed into BL21 (DE3) cells (Stratagene, La Jolla, CA) carrying the pBirAcm plasmid (Avidity, Denver, CO) that encodes biotin ligase. DNA sequencing confirmed the presence of the gene encoding Dxr in the TYB2AT plasmid. Western blot analysis of induced cell lysate using streptavidin-conjugated alkaline phosphatase (Pierce Biotechnology, Rockford, IL) confirmed expression of the biotinylated fusion protein.
Dxr was purified by affinity chromatography of the fusion protein on chitin beads followed by intein-mediated cleavage between Dxr and the intein-CBD according to the manufacturer's protocol (NEB). The biotinylated Dxr liberated by the cleavage was dialyzed into storage buffer (25 mM Tris-HCl [pH 7.7], 100 mM NaCl, 1 mM DTT, 0.2 mM EDTA, and 40% glycerol) and stored at -20°C. The protein appeared to be > 99% pure on an SDSpolyacrylamide gel and biotinylated as assessed by complete binding of the purified protein to streptavidin beads (Promega Corp., Madison, WI).
Phage display
Immulon 4 96-well plates (Dynatech, Thermo Labsystems, Franklin, MA) were coated with streptavidin (1 µg/well) in 0.1 M sodium bicarbonate and blocked with 1% bovine serum albumin (BSA). Biotinylated Dxr (4 pmol/well) diluted into TBST (10 mM Tris-HCl [pH 8.0], 150 mM NaCl, 0.05% Tween-20) was allowed to bind to the plate for 1 h at room temperature. Plates were washed with TBST, and phage from each of 20 proprietary recombinant M13 libraries (total complexity of 2 × 10 10 ) were allowed to bind for 1 h at room temperature. Plates were washed again, and the bound phage were eluted, amplified, and used for the next round of phage selection as described. 25 After 3 to 4 rounds of selection, phage pools were plated for single plaques, purified, and the DNA sequence of individual isolates determined. Phage were tested for their relative affinities for the target protein, as well as affinity to several irrelevant control proteins. The displayed peptides of the phage with the highest affinities and no discernable binding to control proteins were synthesized to include the 12-to 15-amino acid sequence followed by a linker and biotinylated at the C-terminus for labeling.
Time-resolved fluorescence assays
TRF assays to characterize peptide binding to Dxr were performed at room temperature as follows: serial dilutions of the biotinylated peptide diluted in TBST (20 µL/well) were added to a 384-well streptavidin-coated black polystyrene plate (Pierce #15407). The initial peptide solution contained the peptide at 400 nM, and 2-fold serial dilutions were performed. After incubation for 1 h at room temperature, 10 µL of 50 µM biotin in TBST was added to block the remaining biotin binding sites, and the plate was placed at 4°C until used in the assay. A europium-streptavidinbiotinylated Dxr conjugate was prepared as follows: a mixture of 80 nM biotinylated Dxr and 20 nM europium-conjugated streptavidin in TBST was incubated on ice for 30 min. An equal volume of 50 µM biotin in TBST was added to block the remaining biotin binding sites, and 2-fold serial dilutions were performed. After washing the peptide-coated plate, the conjugate solution (20 µL/well) was added to each well, forming a matrix of protein and peptide concentrations. The plate was incubated for 1 h at room temperature and washed 3 times in TBST prior to the addition of 25 µL of europium enhancement solution to each well. Fluorescence readings were obtained on an LJL Analyst reader (Molecular Devices Corp., Sunnyvale, CA) using a less than 400-nm excitation filter and a 620-nm emission filter.
The fosmidomycin and NADPH competition experiment was done in a similar manner, except the conjugate was prepared as described below for HTS. The conjugate was preincubated for 30 min at room temperature with aliquots from 3-fold serial dilutions of fosmidomycin and/or NADPH before addition to the peptide on the plate.
HTS assay
The assay was carried out in 384-well streptavidin-coated black polystyrene plates (Pierce #15407), and liquids were dispensed with a Quadra 384 (Tomtec). The biotinylated screening peptide (100 nM; 20 µL/well) was added to each well and incubated for 1 h at room temperature. Biotin (50 µM; 10 µL/well) was added to each well to block unoccupied sites on streptavidin. The plates were incubated for 30 min at room temperature, after which they were sealed and stored overnight at 4°C. The following day, the peptide-coated plates were allowed to warm to room temperature and washed 3 times with TBST, and mixtures of a Dxrstreptavidin-europium conjugate with individual compounds (20 µL/well, prepared as described below) were transferred to the peptide-coated plates. After 30-min incubation at room temperature, the plates were washed 3 times with TBST, and enhancement solution was added (25 µL/well). After a 15-min incubation, fluorescence was measured on an LJL Analyst reader; data were analyzed with output to Excel (Microsoft) and Spotfire DecisionSite (Spotfire, Inc., Somerville, MA).
The Dxr-streptavidin-europium conjugates were made as follows: a mixture of 50 nM biotinylated Dxr and 12.5 nM europiumconjugated streptavidin in TBST was incubated for 30 min on ice. Unoccupied sites on streptavidin were then blocked by the addition of biotin (5 µM final concentration).
The conjugate-compound mixtures were made as follows: compounds were diluted in 384-well plates to 20 µM (15 µL/well) in 1% DMSO, 10 mM HEPES (pH 8.0). Negative control wells (16 per plate) contained 1% DMSO, 10 mM HEPES (pH 8.0); positive control wells (16 per plate) contained fosmidomycin (40 µM) and NAPDH (40 µM) in 1% DMSO, 10 mM HEPES (pH 8.0). An equal volume of Dxr-streptavidin-europium conjugate (15 µL/ well) was added to each compound-containing well and incubated for 30 min at room temperature. These conjugate-compound mixtures were then added to the peptide-coated wells as described above.
Enzyme assays and data analysis
For measurement of Dxr activity, reactions were run in triplicate at room temperature in a buffer containing 100 mM Tris-HCl (pH 8), 1 mM MnCl 2 , and 0.1% BSA. DMSO was also present at a concentration of 2% from the addition of compounds or control solvent. Dxr and the compound to be tested (25 µL each) were mixed and incubated for 30 min at room temperature in wells of a 96-well microplate (Costar 9016). An equal volume (50 µL) of a substrate mixture consisting of DXP and NADPH was added to the wells to initiate the reaction. Final concentrations were 250 µM DXP and 500 µM NADPH (representing the K m value and a saturating concentration, respectively; unpublished data and Kuzuyama et al 26 ) and 10 to 100 nM Dxr. Compound concentrations were varied from 0.1 to 100 µM by 3-fold serial dilution. Control reactions lacked enzyme, and data from these reactions were used to make corrections for the spontaneous rate of NADPH oxidation. The progress of the reactions was followed at 340 nm in a SpectraMax 190 spectrophotometric plate reader (Molecular Devices, Sunnyvale, CA), with vortexing and reading of the plate every 15 sec. Inhibitor data were fit to a model of competitive binding using Prism (GraphPad Software, Inc., San Diego, CA).
For measurement of glucose-6-phosphate dehydrogenase (G6PD) activity, compounds were preincubated with enzyme as described above, and then the substrates glucose-6-phosphate (G6P) and NADP + were added. Final concentrations were 13 µg/ mL enzyme, 100 µM G6P, and 100 µM NADP + . The progress of the reactions was followed spectrophotometrically.
RESULTS
Development of a surrogate ligand assay
We developed a screening assay for Dxr inhibitors that is based on the ability of compounds to compete with a peptide "surrogate ligand" for binding to the target. To identify suitable surrogate ligands, we used phage display to identify peptides that bound to purified biotinylated Dxr immobilized on a streptavidin-coated plate. A total of 49 phage-displayed peptides, most with related but not identical amino acid sequences, were identified. Each of these phage-displayed peptides bound to Dxr but not to any of several unrelated control proteins (data not shown). Phage were tested for their relative affinities for Dxr in phage titration experiments. Several phage-displayed peptides with the highest affinities were synthesized, each with a C-terminal biotin suitable for conjugation to streptavidin. Each peptide was affixed to a streptavidin-coated microplate, and binding of a europium-streptavidin-biotinylated Dxr conjugate to each peptide was measured by TRF; the assay format is depicted in Figure 2 . Binding curves for 1 peptide (eventually used for the screening assay) at several concentrations of protein are shown in Figure 3 . Peptide binding to Dxr was dose dependent and saturable. This peptide did not bind to several other target proteins that were tested. In addition, it was competitively displaced by unlabeled versions of other Dxr-specific peptides, in-dicating that the peptides all bind to the same site on the protein (data not shown).
Competition experiments were performed with fosmidomycin and NADPH to determine if the peptide binds to a functional site on Dxr. Fosmidomycin, NADPH, or an equimolar mixture of fosmidomycin and NADPH was preincubated with the europiumstreptavidin-biotinylated Dxr conjugate. This solution was then transferred to a microplate to which the peptide was immobilized. The plate was washed and read to determine if these compounds prevented the peptide from binding to Dxr. Figure 4 shows the resulting titration curves for these compounds. Fosmidomycin alone did not reduce peptide binding and NADPH was only weakly competitive with the peptide, but the combination of fosmidomycin and NADPH was very effective in preventing peptide binding. These data suggest that the peptide binds to or overlaps the binding 
HTS for compounds that displace the surrogate ligand
To search for inhibitors of Dxr, HTS was carried out with 32,000 structurally diverse, historical compounds from the Specs collection, using the assay format illustrated in Figure 2 . Positive control wells on each plate contained both fosmidomycin and NADPH, whereas negative control wells contained buffer. The screen statistics are summarized in Table 1 , with Z′ values calculated as described. 27 Of 32,000 compounds screened, the 320 (1%) most inhibitory compounds (Fig. 5 ) were handpicked and reassayed in quadruplicate, using the same conditions that were used in the primary screen. Using a cutoff of 50% inhibition, 89 compounds were confirmed as hits, for an overall hit rate of 0.28%. Visual inspection of the structures of these compounds showed that they fell into several structural classes (data not shown).
To assess specificity, 11 of the most potent compounds were tested in an assay for glucose-6-phosphate dehydrogenase. The compounds, which had IC 50 values in the Dxr enzyme assay rang- ing from 0.4 to 19 µM, were tested at a concentration of 100 µM in the G6PD assay. No inhibition of the G6PD-catalyzed reaction was detected for any of the compounds.
DISCUSSION
To discover new inhibitors of Dxr, we conducted a novel HTS for compounds that bind to a functionally relevant site. Although Dxr activity is measurable using a spectrophotometric enzyme assay, this assay is not ideally suited to HTS. One problem with the spectrophotometric assay is that the substrate NADPH has a low K m (< 20 µM, the lowest concentration for which reliable data could be obtained; unpublished data). The spectrophotometer is not sufficiently sensitive to measure changes on the order of 0.5 to 1 µM NADPH (which would be necessary to detect competitive inhibition at the NADPH site without depleting substrate). In addition, NADPH slowly oxidizes at room temperature, necessitating control reactions lacking enzyme on each plate for "background" correction. The surrogate ligand-binding assay relies on measurement of fluorescence, and the reagents are relatively stable; thus, the assay is more sensitive and reliable than a spectrophotometric assay. The assay was also well suited for an enzyme whose substrate was difficult to obtain: at the time this work was initiated, the DXP substrate was not commercially available. Once DXP became available, we were able to use it to confirm that 60% of the inhibitors in the surrogate ligand assay were indeed inhibitors in the Dxr enzyme assay.
The Z′ value of the HTS was negative, implying poor discrimination of hits from the random noise in the assay. This was due to high deviations in the assay and a low signal-to-background ratio on the day of the screen. These parameters improved during the confirmation process (Table 1) . For this assay, we had the ability to confirm these hits in a biochemical assay-based secondary screen. The useful and biochemically relevant results of the Dxr screen demonstrate that hit characterization and lead generation are of primary importance in judging the success of a screen, as opposed to reliance on statistical concerns alone. However, we have performed many peptide-based surrogate ligand screens for other targets, and typical Z′ values for these assays are in the range of 0.4 to 0.7.
We investigated the nature of the Dxr-surrogate ligand interaction. The peptide surrogate ligand could be competed from Dxr by the combination of fosmidomycin and NADPH but not by each individually. Because fosmidomycin structurally resembles the substrate DXP, this finding suggests that the peptide binds to or physically overlaps both the DXP and NADPH sites. A second possibility is that when fosmidomycin and NADPH are bound, they allosterically prevent binding of the peptide to a different (nonsubstrate) site on Dxr by a conformational change. In either case, binding of the peptide and substrates appears to be mutually exclusive. The fact that the screening hits are enzyme inhibitors argues that they interact either with the active site or an important allosteric regulatory site. The compounds may prevent either or both substrates from binding to the enzyme; that they are effective under conditions of saturating NADPH and nonsaturating DXP concentrations suggests that they at least affect the DXP site. It is also possible that the compounds that do not inhibit the enzyme assay bind predominantly at the NADPH site but do not effectively compete at the saturated concentrations of NADPH used in the enzyme assay. As mentioned above, inhibition of Dxr at the NADPH site is difficult to detect because of the necessity of working at low NADPH concentrations close to the K m . Use of cuvettes with a path length longer than the 1-cm standard might increase the sensitivity of the low-throughput enzyme assay sufficient to detect inhibition at the NADPH site.
The specificity of the compounds for Dxr was tested by measuring their effect on the activity of G6PD. This enzyme is similar to Dxr in that it binds both a sugar phosphate and a nicotinamide adenine dinucleotide phosphate. If the Dxr-inhibitory compounds had a generalized effect on binding of sugar phosphate or NADPH, those compounds would be expected to inhibit G6PD activity. None of the identified Dxr inhibitors had any impact on the activity of G6PD. Furthermore, the lack of effect on G6PD was seen even at compound concentrations far higher than the IC 50 values of many of these compounds for Dxr, which shows that they are not nonspecific denaturants. As would be expected for specific enzyme inhibitors, the compounds fell into a limited number of structurally distinct classes. The structure-activity relationships seen with these compounds will be a starting point for lead optimization.
The approach demonstrated here using Dxr can be extended to a wide variety of targets. In particular, targets with difficult biochemical assays are good candidates for peptide-based surrogate ligand technology. Such targets include those with substrates that are dif- ficult to synthesize or expensive to obtain, those that normally function as part of multiprotein complexes (such as DNA replication enzymes), and those with assays that require a separation step. Any of these conditions might render the formatting of an HTS difficult or impossible. Once compound hits have been identified in the surrogate ligand HTS, they can be confirmed as inhibitors in the low-throughput biochemical assay. Targets of unknown function are also excellent candidates for surrogate ligand assay development, as no prior knowledge of biochemical activity is required to format this type of assay. Genome sequencing has revealed many potential drug targets whose precise biochemical function is unknown. Once the requirement for a biochemical assay is removed, a screening assay should be easily devised for many of these targets. The surrogate ligand technology described here has the potential to greatly expand the repertoire of available targets for drug discovery.
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